[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100651691":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":25,"locations":35,"responsibleParty":57,"collaborators":61,"id":73,"slug":74,"hasResults":75,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":79,"eligibilityCriteria":80,"healthyVolunteers":75,"sex":81,"minAge":82,"maxAge":10,"enrollmentInfo":83,"targetDuration":86,"studyType":87,"phases":10,"briefSummary":88,"conditions":89,"keywords":91,"overallStatus":38,"whyStopped":10,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":102},{"fullName":5,"class":6},"Xuanwu Hospital, Beijing","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Satralizumab Treatment Group",null,"NMOSD patients receiving Satralizumab at early phase of an NMOSD attack",[13],"Drug: Satralizumab",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":10},"DRUG","Satralizumab","As recommended in the prescribing information, patients will receive subcutaneous satralizumab Injection as part of their routine treatment. The loading dose is 120 mg administered at Weeks 0, 2, and 4, followed by a maintenance dose of 120 mg every 4 weeks. Maintenance treatment is recommended for a minimum duration of 24 weeks.",[9],[21],{"name":22,"affiliation":23,"role":24},"Junwei Hao, MD, PhD","Xuanwu Hospital Department of Neurology","PRINCIPAL_INVESTIGATOR",[26,31],{"name":27,"role":28,"phone":29,"phoneExt":10,"email":30},"Xixi Yang, MD, PhD","CONTACT","+86 15601179281","xyang891@outlook.com",{"name":32,"role":28,"phone":33,"phoneExt":10,"email":34},"Zheng Liu, MD, PhD","+86 13754093891","lzwcy@xwhosp.org",[36],{"facility":37,"status":38,"city":39,"state":40,"zip":41,"country":42,"countryCode":43,"cosmosGeoPoint":44,"geoPoint":49,"contacts":50},"Xuanwu Hospital Capital Medical University","RECRUITING","Beijing","Beijing Municipality","100053","China","CN",{"type":45,"coordinates":46},"Point",[47,48],116.39723,39.9075,{"lat":48,"lon":47},[51,53,55],{"name":27,"role":28,"phone":52,"phoneExt":10,"email":30},"+8615601179281",{"name":32,"role":28,"phone":54,"phoneExt":10,"email":30},"+8613754093891",{"name":27,"role":56,"phone":10,"phoneExt":10,"email":10},"SUB_INVESTIGATOR",{"type":58,"investigatorFullName":59,"investigatorTitle":60,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"SPONSOR_INVESTIGATOR","Junwei Hao, MD","Professor",[62,64,66,68,71],{"name":63,"class":6},"The First Hospital of Hebei Medical University",{"name":65,"class":6},"The Second Hospital of Hebei Medical University",{"name":67,"class":6},"First Affiliated Hospital of Harbin Medical University",{"name":69,"class":70},"Shandong Provincial Hospital","OTHER_GOV",{"name":72,"class":6},"Chifeng Municipal Hospital","100651691","a-multicenter-prospective-real-world-effectiveness-and-safety-of-satralizumab-in-the-early-treatment-of-attacks-in-nmosd-100651691",false,"NCT07762872","A Multicenter Prospective Real-World Effectiveness and Safety of Satralizumab in the Early Treatment of Attacks in NMOSD","Real-World Effectiveness and Safety of Satralizumab in the Early Treatment of Attacks in Neuromyelitis Optica Spectrum Disorder: A Multicenter Prospective Cohort Study","SATURN","Inclusion Criteria:\n\n* Diagnosis of AQP4-IgG-positive NMOSD\\* and age ≥ 18 years; EDSS score ≤ 8.5 during an acute relapse in NMOSD patients; NMOSD patients experiencing an acute relapse who are scheduled to receive or are currently receiving recommended acute-phase treatments-including intravenous methylprednisolone, IVIG, PE, or PA; Receiving Satralizumab treatment; Patient understands the study procedures and has signed the informed consent form indicating willingness to participate in the study.\n\nExclusion Criteria:\n\n* Patients with NMOSD who received other biologics (e.g., rituximab, inebilizumab, tocilizumab, eculizumab) either within the past 6 months prior to this acute exacerbation or during the current acute phase; Patients with contraindications to Satralizumab, including: known allergy to Satralizumab or any inactive ingredient, active Hepatitis B infection, active or therapy-naive latent tuberculosis; Pregnant or lactating women; Patients with concomitant Neoplasm malignant or other severe diseases; Patients currently enrolled in other interventional clinical studies; Patients assessed by the investigator\u002Fresearch staff as having a Critical illness or any Mental disorder or Cognitive disorder that may interfere with the study and who are unable to complete the key assessments required by this protocol; patients assessed by the investigator\u002Fresearch staff as unlikely to attend scheduled follow-up assessments under routine clinical care.","ALL","18 Years",{"count":84,"type":85},50,"ESTIMATED","3 Months","OBSERVATIONAL","This study is a multicenter, prospective cohort study designed to enroll 50 NMOSD patients who receive Satralizumab treatment during the early phase of an NMOSD attack. Follow-up visits will be conducted at baseline, 3 months, and 6 months to record and assess EDSS scores, modified Rankin Scale (mRS) scores, EQ-5D scores, Activities of Daily Living (ADL) scores, relapse events, safety data, and exploratory endpoints (e.g., blood inflammatory markers and visual function), with the aim of evaluating the efficacy and safety of Satralizumab in the early treatment of NMOSD-thereby providing patients with more effective therapeutic options and further optimizing the clinical management of NMOSD.",[90],"Neuromyelitis Optica Spectrum Disorders (NMOSD)",[92,17],"NMOSD","2026-08-12",{"date":95,"type":96},"2026-08-13","ACTUAL",{"date":98,"type":96},"2026-07-20",{"date":100,"type":85},"2028-01-20",{"name":59,"class":6},1]